I’d like personally to welcome each of you to the conference ‘Autism and Fragile X-associated
Disorders’, the first such conference not only in Serbia but also in our region of Southeast Europe.
The world of fragile X is an exciting area for researchers and medical professionals: connecting us
bringing experts and inspired people together in a high-profile conference like this. The conference
will be a great opportunity to share the latest knowledge in the field of autism and fragile X. It
would also allow you to experience the unique environment of Belgrade, one of the oldest cities in
Europe and the only one built on the confluence of two large international rivers, Sava and Danube,
which is at a core of ancient world civilisation.
Thank you for your participation, and I look forward to seeing you in Belgrade, Serbia.
Dragana Protic, MD, PhD
School of Medicine, University of Belgrade
Randi Hagermen, MD
Dear Conference Attendees,
It is my great pleasure to welcome all of you to the First International Conference of Fragile X
Syndrome and Associated Disorders and Autism in Serbia. This conference has been envisioned by Dr
Dragana Protic MD, PhD and her collaborators because of the need to bring new treatments to the
of Serbia and entire region. There is also a need to initiate further research in Fragile X disorders
at your great Universities so that the biology of these disorders can be better understood and new
treatments can be developed here.
Randi Hagerman, MD
Medical Director of the MIND Institute
Endowed Chair in Fragile X Research
UC Davis Medical Center
Dejan B. Budimirovic, MD
I am thrilled to welcome all of you to the conference ‘Autism and Fragile X-associated Disorders’ in
Belgrade, Serbia. This exciting conference brings the latest knowledge in the field of fragile X
syndrome (FXS). FXS is the most common known single gene medical/genetic cause of autism spectrum
disorder (ASD), which is an enormous and growing public health problem throughout the world. As the
most studied model of ASD, which is purely behaviourally defined, I would like to underscore
preclinical breakthrough studies in FXS over the past 25 years as researchers in the field have
identified a number of potential targeted therapeutics. Such remarkable progress has allowed over 20
controlled clinical trials to date, and counting. Hence, FXS is the most translated into clinical
trials among all neurodevelopmental disorders, including idiopathic ASD.
Together we continue to build the future in fragile X field that is also of interest for at least a
subset of ASD.
On behalf of my colleagues from the USA and Serbia, I am looking forward to seeing you in Belgrade.
Dejan B. Budimirovic, MD
Johns Hopkins University School of Medicine
Medical co-Director, Fragile X Clinic
Kennedy Krieger Institute/the Johns Hopkins Medical Institutions
As a representative of both the National Fragile X Foundation and the UC Davis MIND Institute, I am
excited about this great opportunity to expand awareness about autism and Fragile X. The joining of
American and Serbian professionals is sure to bring greater knowledge and improved treatments for
families in Central Europe and beyond. We thank our Serbian colleagues and, in particular, Dr.
Protic, for making this possible.
National Fragile X Foundation
MIND Institute, UC Davis